Company intelligence / Profile preview

NuGenerex Health

USA

Ownership: Private
Development stage: Other

Overview

NuGenerex Immuno-Oncology has achieved Phase 1 trials for its HIV vaccine, conducted preclinical studies for RNA interference therapeutics targeting HIV, and had active (but in some cases later discontinued) clinical programs targeting HER2 in cancer using peptide vaccines. No recent significant commercial clinical results have been reported.

Therapeutic areas: HematologyOncologyInfectious DiseasesImmunology
Modalities: Prophylactic vaccinesiRNAImmunotherapeutic peptidePeptideRNA therapy
Industry: Biotech

Partnerships

Worldwide Digitech (WWDT) LLC (joint venture)Greenwich LifeSciences Inc. (co-development of HER2/Neu GP2 vaccine)

Beyond the preview

Go deeper on NuGenerex Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuGenerex Health.

Explore the full profile